Greenwich LifeSciences, Inc.
GLSI
$16.80
$0.422.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.92% | -18.71% | -13.83% | 54.45% | 49.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.23% | 20.96% | 5.79% | 89.73% | 80.09% |
| Operating Income | -15.23% | -20.96% | -5.79% | -89.73% | -80.09% |
| Income Before Tax | -15.15% | -21.45% | -6.63% | -93.52% | -84.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.15% | -21.45% | -6.63% | -93.52% | -84.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.15% | -21.45% | -6.63% | -93.52% | -84.25% |
| EBIT | -15.23% | -20.96% | -5.79% | -89.73% | -80.09% |
| EBITDA | -15.25% | -20.98% | -5.80% | -89.77% | -80.11% |
| EPS Basic | -7.27% | -14.27% | -2.15% | -88.40% | -79.66% |
| Normalized Basic EPS | -7.28% | -14.27% | -2.13% | -88.42% | -79.69% |
| EPS Diluted | -7.27% | -14.27% | -2.15% | -88.40% | -79.66% |
| Normalized Diluted EPS | -7.28% | -14.27% | -2.13% | -88.42% | -79.69% |
| Average Basic Shares Outstanding | 7.47% | 6.03% | 3.99% | 3.04% | 2.66% |
| Average Diluted Shares Outstanding | 7.47% | 6.03% | 3.99% | 3.04% | 2.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |